



US007361352B2

(12) **United States Patent**
Birkett et al.

(10) **Patent No.:** **US 7,361,352 B2**
(45) **Date of Patent:** **Apr. 22, 2008**

- (54) **INFLUENZA IMMUNOGEN AND VACCINE**
- (75) Inventors: **Ashley J. Birkett**, Escondido, CA (US);
Walter Fiers, Destelbergen (BE)
- (73) Assignees: **Acambis, Inc.**, Cambridge, MA (US);
Vlaams Interuniversitair Instituut voor Biotechnologie, Zwinjaarde (BE)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: **10/787,734**
- (22) Filed: **Feb. 26, 2004**
- (65) **Prior Publication Data**
US 2006/0115489 A1 Jun. 1, 2006

EP	421635 B1	4/1991
EP	671948 B1	9/1995
EP	689454 B1	1/1996
GB	2122204 A	1/1984
WO	WO 91/13922	9/1991
WO	WO 95/17210	6/1995
WO	WO 96/02555	2/1996
WO	WO 96/33739	10/1996
WO	WO 99/07839	2/1999
WO	WO 99/12565	3/1999
WO	WO 99/40934	8/1999
WO	WO 99/52549	10/1999
WO	WO 00/32625	6/2000
WO	WO 01/27281	4/2001
WO	WO 01/41759	6/2001
WO	WO 01/98333	12/2001
WO	WO 02/13765	2/2002
WO	WO 02/13765 A2	2/2002
WO	WO 02/14478	2/2002

Related U.S. Application Data

- (63) Continuation-in-part of application No. 10/732,862, filed on Dec. 10, 2003, which is a continuation-in-part of application No. PCT/US03/05196, filed on Feb. 21, 2003, which is a continuation-in-part of application No. 10/274,616, filed on Oct. 21, 2002, now abandoned, which is a continuation-in-part of application No. 10/082,014, filed on Feb. 21, 2002, now abandoned.

- (51) **Int. Cl.**
A61K 39/29 (2006.01)
A61K 39/00 (2006.01)
- (52) **U.S. Cl.** **424/189.1; 424/184.1; 424/185.1; 424/186.1; 424/192.1**
- (58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,539,205 A	9/1985	Goodman et al.	514/45
4,643,992 A	2/1987	Goodman et al.	514/45
4,767,842 A	8/1988	Stevens	530/324
4,987,237 A	1/1991	Myers et al.	549/222
5,011,828 A	4/1991	Goodman et al.	514/45
5,023,179 A	6/1991	Lam et al.	435/172.3
5,057,540 A	10/1991	Kensil et al.	514/25
5,093,318 A	3/1992	Goodman et al.	514/45
5,110,732 A	5/1992	Benfey et al.	435/172.3
5,297,441 A	3/1994	Smith et al.	73/860
5,387,744 A	2/1995	Curtiss, III et al.	424/235.1
5,618,988 A	4/1997	Hauptmann et al.	800/205
5,656,472 A	8/1997	Ausich et al.	435/193
5,679,880 A	10/1997	Curtiss, III et al.	800/205
5,709,879 A	1/1998	Barchfeld et al.	424/450
5,888,799 A	3/1999	Curtiss, III	435/252.3
5,977,081 A	11/1999	Marciani	
6,024,961 A	2/2000	Curtiss, III et al.	424/200
6,080,725 A	6/2000	Marciani	
6,086,901 A	7/2000	O'Hagan et al.	424/283.1
6,231,864 B1	5/2001	Birkett	424/189.1

FOREIGN PATENT DOCUMENTS

EP 399 843 B1 11/1990

OTHER PUBLICATIONS

- Neiryneck S. et al. "A universal influenza A vaccine based on the extracellular domain of the M2 protein". *Nat. Med.* Oct. 1999;5(10):1157-63.*
- Pumpens et al. "Hepatitis B virus core particles as epitope carriers. *Intervirology*". 1995;38(1-2):63-74.*
- Tsuda "Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis" *Vox sang* 1998, 74(3):148-55.*
- Baldrige "Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines". *Methods. Sep.* 1999;19(1):103-7.*
- He "Calcium phosphate nanoparticle adjuvant". *Clin Diagn Lab Immunol.* Nov. 2000;7(6):899-903.*
- Castrucci M. "The cysteine residues of the M2 protein are not required for influenza A virus replication". *Virology.* Nov. 10, 1997;238(1):128-34.*
- Zebezee "Influenza A virus M2 protein: monoclonal antibody restriction of a virus growth and detection of M2 in virions". *J Virol.* Aug. 1988;62(8):2762-72.*
- Benfey et al., "Regulated Genes in Transgenic Plants", *Science* (Apr. 1989) 244:174-181.

(Continued)

Primary Examiner—Bruce R. Campell
Assistant Examiner—Bo Peng
(74) *Attorney, Agent, or Firm*—Edward P. Gamson; Welsh & Katz Ltd.

(57) **ABSTRACT**

A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop sequence. The HBc chimera preferably contains an influenza-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimeras are also disclosed.